PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
2.
RudickRAStuartWHCalabresiPA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
3.
Kleinschmidt-DeMastersBKTylerKL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med2005; 353: 369–374.
4.
Langer-GouldAAtlasSWGreenAJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med2005; 353: 375–381.
5.
KeanJMRaoSWangM, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog2009; 5: e1000363.
6.
SunyaevSRLugovskoyASimonK, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet2009; 5: e1000368.
7.
GorelikLLernerMBixlerS, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol2010; 68: 295–303.
8.
SorensenPSBertolottoAEdanG, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler2012; 18: 143–152.
9.
KapposLBatesDEdanG, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol2011; 10: 745–758.
10.
VermerschPKapposLGoldR, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology2011; 76: 1697–1704.
